The new highly selective, fully human monoclonal antibody, abelacimab has been designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition. It shows dual inhibitory activity against both
These therapies will be developed using Ryvu’s stimulator of interferon genes (STING) technology. The deal expands Exelixis’ biotherapeutics portfolio by combining its tumour-specific targeting approaches with the Ryvu’s
The latest move follows a strategic multi-year research collaboration of the entities for pre-clinical development of investigational TIL therapies in November last year. Under the expanded collaboration, Turnstone
An investigational anti-amyloid beta (Aβ) protofibril antibody, lecanemab is developed as part of a strategic research alliance between Eisai and BioArctic. It selectively binds to neutralise and eliminate
Mogrify has developed a suite of platform technologies that use a systematic big-data approach for direct cellular reprogramming and to maintain cell identity. Its epiMOGRIFY and MOGRIFY platforms
The intent to acquire Libtayo was announced on 2 June this year. The two companies entered into an immuno-oncology license and collaboration agreement in 2015. As per the terms of
As part of the collaboration, the companies will carry out an observational study in chronic metabolic disease patients as well as those with increased risk of complications like
As part of the collaboration, both the companies will conduct research and preclinical development activities together for identifying new monovalent small molecules which regulate target proteins via stabilisation,
An investigational T-cell redirecting bispecific antibody, Talquetamab targets GPRC5D, a new multiple myeloma cells target, and CD3, a component of the T-cell receptor. The bispecific antibody is indicated
As part of the collaboration, the companies will co-develop Bifunctional HER2-Sialidase, which is currently in preclinical development stage, and a second bifunctional sialidase that is to be developed
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.